[HTML] springer.comFull View

[HTML][HTML] Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …

F Bai, T Beringheli, V Vitaletti, A Santoro, F Molà… - Infectious Diseases and …, 2024 - Springer
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
相关文章

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …

F Bai, T Beringheli, V Vitaletti, A Santoro… - Infectious diseases … - pubmed.ncbi.nlm.nih.gov
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …

F Bai, T Beringheli, V Vitaletti, A Santoro… - Infectious Diseases …, 2024 - europepmc.org
Methods We conducted a retrospective study enrolling HR patients with mild-to-moderate
COVID-19 (Jan-Oct 2022) treated with nirmatrelvir/ritonavir or molnupiravir or 3 days of …
[PDF] researchgate.net

[PDF][PDF] Clinical Outcome and 7‑Day Virological Clearance in High‑Risk Patients with Mild–Moderate COVID‑19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …

F Bai, T Beringheli, V Vitaletti, A Santoro, F Molà… - researchgate.net
Methods: We conducted a retrospective study enrolling HR patients with mild-to-moderate
COVID-19 (Jan–Oct 2022) treated with nirmatrelvir/ritonavir or molnupiravir or 3 days of …